My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 177

    1.

    Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab.

    Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M.

    Ann Intern Med. 2007 Nov 20;147(10):699-702.PMID: 18025446 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM.

    N Engl J Med. 2001 Oct 11;345(15):1098-104.PMID: 11596589 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    [Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003]

    Baldin B, Dozol A, Spreux A, Chichmanian RM.

    Presse Med. 2005 Mar 12;34(5):353-7. French. PMID: 15859568 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.

    Kaur N, Mahl TC.

    Dig Dis Sci. 2007 Jun;52(6):1481-4. Epub 2007 Apr 11.PMID: 17429728 [PubMed - indexed for MEDLINE]Related articles

    5.

    Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

    Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM.

    Ann Intern Med. 2003 May 20;138(10):807-11. Review.PMID: 12755552 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

    Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM.

    J Drugs Dermatol. 2008 Dec;7(12):1137-46.PMID: 19137767 [PubMed - indexed for MEDLINE]Related articles

    7.

    Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.

    Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG.

    Pharmacoepidemiol Drug Saf. 2006 Jan;15(1):11-8.PMID: 16136625 [PubMed - indexed for MEDLINE]Related articles

    8.

    Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis.

    Figueiredo IT, Morel J, Sany J, Combe B.

    Clin Exp Rheumatol. 2008 Jan-Feb;26(1):18-23.PMID: 18328142 [PubMed - indexed for MEDLINE]Related articles

    9.

    Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride.

    Shaffer D, Butterfield M, Pamer C, Mackey AC.

    J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-5.PMID: 15637848 [PubMed - indexed for MEDLINE]Related articles

    10.

    Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease.

    Gupta A, Street AC, Macrae FA.

    Med J Aust. 2008 Feb 4;188(3):168-70.PMID: 18241178 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience.

    Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, Maggi E.

    Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):367-74.PMID: 18547481 [PubMed - indexed for MEDLINE]Related articles

    12.

    Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004.

    Zinderman CE, Landow L, Wise RP.

    J Vasc Surg. 2006 May;43(5):1004-9. Epub 2006 Apr 5.PMID: 16678697 [PubMed - indexed for MEDLINE]Related articles

    13.

    Infliximab does not suppress the tuberculin skin test (purified protein derivative).

    Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H.

    J Rheumatol. 2007 Mar;34(3):474-80. Epub 2007 Feb 1.PMID: 17299840 [PubMed - indexed for MEDLINE]Related articles

    14.

    Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action.

    Brinker AD, Beitz J.

    Am J Hematol. 2002 Aug;70(4):313-7.PMID: 12210813 [PubMed - indexed for MEDLINE]Related articles

    15.

    Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

    Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N.

    Drug Saf. 2007;30(10):891-8.PMID: 17867726 [PubMed - indexed for MEDLINE]Related articles

    16.

    Miliary tuberculosis following infliximab therapy for Crohn disease: A case report and review of the literature.

    Stas P, D'Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S.

    Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):217-20. Review.PMID: 16929619 [PubMed - indexed for MEDLINE]Related articles

    17.

    Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.

    DE Oliveira JP, Levy A, Morel P, Guibal F.

    J Dermatol. 2008 Sep;35(9):575-80.PMID: 18837702 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Chemoprophylaxis for tuberculosis]

    Yamagishi F.

    Kekkaku. 2005 Oct;80(10):647-53. Review. Japanese. PMID: 16296393 [PubMed - indexed for MEDLINE]Related articles

    19.

    Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.

    Hartnell NR, Wilson JP.

    Pharmacotherapy. 2004 Jun;24(6):743-9.PMID: 15222664 [PubMed - indexed for MEDLINE]Related articles

    20.

    Re-activation of bovine tuberculosis in a patient treated with infliximab.

    Larsen MV, Sørensen IJ, Thomsen VØ, Ravn P.

    Eur Respir J. 2008 Jul;32(1):229-31.PMID: 18591340 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity